LTRN · Lantern Pharma Inc
United States · RS rating 4 · As of 2026-11-03
| Price | 0.60 USD |
|---|---|
| 1-day change | -5.9% |
| RS rating (overall / 1M / 3M / 12M) | 4 / 9 / 3 / 7 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 16 / 5 / 31 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -90.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +85.6% |
| Market cap (USD) | $26.0M |